Tag: carcinoid syndrome

New Survey for the Carcinoid Syndrome Community

Dear Friends,

We are excited to invite you to participate in the new Carcinoid Syndrome Impact Survey, which is designed to help better understand the impact that carcinoid syndrome has on patients’ lives, while also exploring physicians’ treatment…

OncLive Features Neuroendocrine Tumors in Videos and News Articles

Chemotherapy Options in Neuroendocrine Tumors is the latest video to be released in the OncLive series on Neuroendocrine Tumors. Matthew H. Kulke, MD, Director of the Program in Neuroendocrine and Carcinoid-Tumors at Dana-Farber/Brigham and Women’s…

Lexicon’s Carcinoid Syndrome Treatment Meets Primary Endpoint in Phase III Clinical Trial

Lexicon Pharmaceuticals Inc. has announced that the pivotal phase III clinical trial, TELESTAR, of its oral drug candidate telotristat etiprate met the primary endpoint in treating cancer patients with carcinoid syndrome that is not adequately controlled…

DENIED: Michael Farris’ Journey with Insurance for Neuroendocrine Cancer Treatment

The good news is the very positive result at the end – but the road to getting insurance coverage for Michael Farris’ participation in the PRRT (peptide receptor radionuclide therapy) clinical trial at Excel Diagnostics in Houston, Texas, was fraught…

Lexicon Pharmaceuticals, Inc. Continues Recruiting for Phase 3 Studies in Carcinoid Syndrome

Many patients face the challenge of controlling carcinoid syndrome which can persist even while being treated with somatostatin analog (SSA) therapy. For patients on SSA therapy who continue to experience conditions such as diarrhea, frequent bowel…

WEGO Health Builds Online Carcinoid Community

You can make a difference! To learn more about the needs of the carcinoid patient community, WEGO Health is conducting a survey and would appreciate your input.

To reach out to the carcinoid community, WEGO Health has created a survey to learn more about…

Novartis Offers New Sandostatin LAR Depot Co-Pay Assistance Program

A new co-pay assistance program for carcinoid syndrome patients taking Sandostatin® LAR Depot has been established by Novartis Pharmaceuticals Corporation, effective February 2014.

With the Sandostatin® LAR Depot Co-Pay Assistance Program, eligible…

Mobile Survey for Carcinoid Syndrome Community

Carcinoid syndrome patients, caregivers, and advocates in the carcinoid syndrome community are invited to participate in an exclusive mobile survey being conducted by WEGO Health via Truvio.

WEGO Health is an organization committed to empowering…

10 Highlights of the Year 2013 for the Carcinoid and Neuroendocrine Tumor Community

As the Carcinoid Cancer Foundation looks back on the year 2013, we reached out to physicians, patients, support group leaders, listserv managers, patient advocates, and business colleagues to see what they thought were among the highlights of the past…

Discover Something New in Carcinoid Syndrome

For patients who suffer from carcinoid syndrome – with symptoms such as diarrhea, frequent bowel movements, abdominal pain, and flushing – that is not adequately controlled by their current somatostatin analog therapy, there is an opportunity to participate…